Hualan Biological Engineering Inc
SZSE:002007
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.84
24.44
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hualan Biological Engineering Inc
Gross Profit
Hualan Biological Engineering Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Hualan Biological Engineering Inc
SZSE:002007
|
Gross Profit
ÂĄ3.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
15%
|
||
Beigene Ltd
HKEX:6160
|
Gross Profit
ÂĄ14.7B
|
CAGR 3-Years
108%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Gross Profit
ÂĄ4.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
335%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Gross Profit
ÂĄ4.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Gross Profit
ÂĄ3.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Gross Profit
ÂĄ9.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
34%
|
Hualan Biological Engineering Inc
Glance View
Hualan Biological Engineering, Inc. engages in the research and development, production, and sale of biological products. The company is headquartered in Xinxiang, Henan and currently employs 2,927 full-time employees. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.
See Also
What is Hualan Biological Engineering Inc's Gross Profit?
Gross Profit
3.1B
CNY
Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Gross Profit amounts to 3.1B CNY.
What is Hualan Biological Engineering Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
15%
Over the last year, the Gross Profit growth was -4%. The average annual Gross Profit growth rates for Hualan Biological Engineering Inc have been -7% over the past three years , 5% over the past five years , and 15% over the past ten years .